RADX.US Radiopharm Theranostics Limited American Depositary Shares

Healthcare Biotechnology USA Stocks
0.6710 USD
Close of Nov 18, 2026
0.6501 10.63
Market cap
USD 10.5M
P/E
-
P/B
0.72x
ROE
-218.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is RADX.US undervalued?

Graham number

The Graham number of Radiopharm Theranostics Limited American Depositary Shares cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Radiopharm Theranostics Limited American Depositary Shares fundamental analysis

No fundamental analysis for Radiopharm Theranostics Limited American Depositary Shares yet.

Radiopharm Theranostics Limited American Depositary Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Radiopharm Theranostics Limited American Depositary Shares

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; …

Full company profile